Key Points
- Seer CFO David Horn sold 7,303 shares on May 20 at an average price of $1.69, worth about $12,342. After the sale, he still owned 493,959 shares.
- Seer’s recent results were mixed: it reported Q1 EPS of -$0.30, matching analyst estimates, but revenue of $2.79 million came in below the $3.60 million consensus.
- Analyst sentiment remains mixed but constructive overall, with a consensus rating of “Buy” and an average price target of $4.00, despite at least one firm maintaining a sell rating.
Seer, Inc. (NASDAQ:SEER - Get Free Report) CFO David Horn sold 7,303 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $1.69, for a total transaction of $12,342.07. Following the completion of the sale, the chief financial officer owned 493,959 shares of the company's stock, valued at approximately $834,790.71. The trade was a 1.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Seer Price Performance
Shares of NASDAQ SEER opened at $1.77 on Friday. The company has a 50 day simple moving average of $1.80 and a 200-day simple moving average of $1.87. The company has a market capitalization of $99.86 million, a P/E ratio of -1.43 and a beta of 1.63. Seer, Inc. has a 1 year low of $1.65 and a 1 year high of $2.41.
Seer (NASDAQ:SEER - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.30). Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%. The business had revenue of $2.79 million during the quarter, compared to the consensus estimate of $3.60 million.
Analysts Set New Price Targets
SEER has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Seer in a research report on Tuesday, April 21st. Canaccord Genuity Group began coverage on shares of Seer in a report on Monday, May 4th. They issued a "buy" rating and a $4.00 target price for the company. Finally, TD Cowen upgraded shares of Seer to a "strong-buy" rating in a report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $4.00.
Check Out Our Latest Stock Report on SEER
Hedge Funds Weigh In On Seer
Several institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its stake in shares of Seer by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company's stock worth $431,000 after acquiring an additional 6,304 shares in the last quarter. Shay Capital LLC grew its stake in shares of Seer by 17.7% in the third quarter. Shay Capital LLC now owns 73,571 shares of the company's stock worth $160,000 after acquiring an additional 11,073 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Seer in the second quarter worth $25,000. Vanguard Group Inc. grew its stake in shares of Seer by 0.9% in the third quarter. Vanguard Group Inc. now owns 2,221,404 shares of the company's stock worth $4,820,000 after acquiring an additional 18,760 shares in the last quarter. Finally, Corient Private Wealth LLC grew its stake in shares of Seer by 46.3% in the second quarter. Corient Private Wealth LLC now owns 63,200 shares of the company's stock worth $135,000 after acquiring an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 75.20% of the company's stock.
About Seer
(
Get Free Report)
Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.
The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
